Compare Regeneron Pharmaceuticals Inc (REGN) vs Starbucks Corp (SBUX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs Starbucks Corp — how do they compare? Regeneron Pharmaceuticals Inc trades at $807.6 (market cap $83.43B), while Starbucks Corp trades at $100.32 (market cap $116.29B). The key difference: Starbucks Corp is the larger of the two by market cap, and Starbucks Corp pays the higher dividend (2.43%). Which is the better fit depends on your goals.
| REGN | SBUX | |
|---|---|---|
Market Cap | $83.43B | $116.29B |
Sector | Health | Consumer Cyclical |
52-Week High | $852.03 | $108.55 |
52-Week Low | $555.51 | $78.46 |
Enterprise Value | $78.14B | $135.12B |
Dividend Yield | 0.46% | 2.43% |
Volume | — | 7,493,833 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $810.31, down 2.1% today, with strong fundamentals including 84.9% gross margins and consistent earnings beats. The stock shows bullish technical signals with support at $805 and resistance at $838, while analyst consensus remains strongly positive with 69% buy ratings. Recent news highlights multiple class action lawsuits related to clinical trial disclosures, creating near-term sentiment headwinds despite solid financial performance.
Outlook remains cautiously optimistic given strong profitability and analyst support, though legal risks and clinical trial uncertainties present challenges. The stock trades above consensus price target of $756.82, suggesting limited near-term upside potential despite robust fundamentals and institutional confidence.
Starbucks (SBUX) trades at $102.01, down 2.35% today, with a bearish technical signal but strong recent earnings beats. Revenue grew to $37.18B in 2025, though net income margin compressed to 5.17%. The stock faces headwinds from high valuation multiples (P/E 58.97) and negative shareholder equity, but analyst consensus remains positive with a $113.60 price target. Recent news highlights CEO Niccol's turnaround progress and record sales from seasonal offerings.
Outlook is mixed: operational improvements and debt reduction support upside, but margin pressure and union disputes pose risks. The stock offers growth potential if execution continues, yet investors must weigh high valuation against competitive and labor challenges in the coffee retail sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About Starbucks Corp
Starbucks Corporation retails, roasts, and provides its own brand of specialty coffee. The Company operates retail locations worldwide and sells whole bean coffees through its sales group, direct response business, supermarkets, and on the world wide web. Starbucks also produces and sells bottled coffee drinks and a line of ice creams.
Read more on SBUX →
